CJC-1295 W/O DAC + Ipamorelin
The most popular GH research combination. CJC-1295 w/o DAC (5mg) paired with Ipamorelin (5mg) in a single vial for convenient combined research protocols.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How CJC-1295 W/O DAC + Ipamorelin Works
This combination pairs a GHRH analog (CJC-1295 w/o DAC) with a ghrelin mimetic (Ipamorelin) for synergistic growth hormone release. CJC-1295 amplifies the GH pulse amplitude via the GHRH receptor, while Ipamorelin initiates the GH pulse via GHS-R1a. Together they produce a larger, more physiological GH release than either peptide alone — without the cortisol/prolactin spikes seen with other secretagogues.
- Binds GHRH receptor on anterior pituitary
- Raises intracellular cAMP in somatotrophs
- Amplifies GH pulse amplitude
- Activates GHS-R1a on pituitary somatotrophs
- Triggers calcium-dependent GH exocytosis
- Selective — does not raise cortisol or prolactin
- Hepatic IGF-1 production increases
- Supports muscle protein synthesis and recovery
- Enhances lipolysis and fat metabolism
CJC-1295 binds the GHRH receptor on somatotrophs, priming the cell for GH release by raising intracellular cAMP. Ipamorelin then activates GHS-R1a on the same cells, triggering calcium influx and GH exocytosis. The dual stimulation at two different receptor points produces synergistic (greater than additive) GH output.
Based on individually published CJC-1295 and Ipamorelin mechanisms.
Preclinical Findings
Research Models
Clinical Data
Synergistic GH Release
The combination of GHRH analogs with ghrelin mimetics is established to produce synergistic GH release. Both CJC-1295 and Ipamorelin have individual clinical data. The combination preserves physiological GH pulsatility without desensitizing the axis.
Individual component publications — see CJC-1295 and Ipamorelin research pages.
Individual clinical studies for each component
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- Ipamorelin is the most selective GHRP — no cortisol, prolactin, or aldosterone increase
- CJC-1295 w/o DAC has short half-life — avoids sustained GH elevation
- Pulsatile dosing preserves hypothalamic feedback sensitivity
- Most common: transient flushing, head rush at time of injection
- No GH-axis suppression with proper dosing protocols
This combination pairs two individually-studied GH secretagogues. For research use only.
About CJC-1295 W/O DAC + Ipamorelin
The most popular GH research combination. CJC-1295 w/o DAC (5mg) paired with Ipamorelin (5mg) in a single vial for convenient combined research protocols.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
